Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 11, 2004, Pages 8-15

  Langer, Corey ^a   Lilenbaum, Rogerio ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b Miami Beach FL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ALOPECIA; ANEMIA; ARTHRALGIA; ASTHENIA; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; INFECTION; KIDNEY DISEASE; LETHARGY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PERFORMANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL; SURVIVAL RATE; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING;

EID: 10044239555     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.10.002     Document Type: Article

References (33)

1. G. Buccheri, D. Ferrigno, M. Tamburini Karnofsky and ECOG performance status scoring in lung cancer A prospective, longitudinal study of 536 patients from a single institution Eur J Cancer 32A 1996 1135 1141
2. J.C. Ruckdeschel, D.M. Finkelstein, D.S. Ettinger A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer J Clin Oncol 4 1986 14 22
3. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC) A multicenter randomized trial Ann Oncol 11 2000 799 805
4. C.J. Sweeney, J. Zhu, A.B. Sandler Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 A phase II trial in patients with metastatic nonsmall cell lung carcinoma Cancer 92 2001 2639 2647
5. P. Kosmidis, N. Mylonakis, C. Nicolaides Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer A phase III randomized trial J Clin Oncol 20 2002 3578 3585
6. Elderly Lung Cancer Vinorelbine Italian Study Group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer J Natl Cancer Inst 91 1999 66 72
7. C. Gridelli, F. Perrone, C. Gallo Chemotherapy for elderly patients with advanced non-small-cell lung cancer The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
8. J.D. Hainsworth, J.B. Erland, J.H. Barton Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status Results of a Minnie Pearl Cancer Research Network phase II trial Clin Lung Cancer 5 2003 33 38
9. C.J. Langer, J. Manola, P. Bernado Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer Implications of Eastern Cooperative Oncology Group 5592, a randomized trial J Natl Cancer Inst 94 2002 173 181
10. R.C. Lilenbaum, J. Herndon, M. List Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC) A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness Proc Am Soc Clin Oncol 21 2002 1a (abstr 2)
11. S.P. Blagden, S.C. Charman, L.D. Sharples Performance status score Do patients and their oncologists agree? Br J Cancer 89 2003 1022 1027
12. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
13. M. Ranson, N. Davidson, M. Nicolson Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer J Natl Cancer Inst 92 2000 1074 1080
14. K. Roszkowski, A. Pluzanska, M. Krzakowski A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) Lung Cancer 27 2000 145 157
15. H. Anderson, P. Hopwood, R.J. Stephens Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--A randomized trial with quality of life as the primary outcome Br J Cancer 83 2000 447 453
16. F.A. Shepherd, J. Pereira, T.E. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st or 2nd line chemotherapy A National Institute of Canada Clinical Trials Group (NCIC CTG) trial Proc Am Soc Clin Oncol Late-Breaking Abstracts Booklet 23 2004 18 (abstr 7022)
17. R. Zinner, A. Govindan, A.J. Wozniak Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small cell lung cancer (NSCLC) treated in the expanded access program (EAP) Proc Am Soc Clin Oncol 23 2004 633 (abstr 7082)
18. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 291 2003 2149 2158
19. R. Lilenbaum, M. Rubin, J. Samuel A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 627 (abstr 7057)
20. P.J. Hesketh, K. Chansky, D.H. Lau Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2 A SWOG phase II trial (S0027) Proc Am Soc Clin Oncol 23 2004 627 (abstr 7056)
21. R.C. Lilenbaum, P. Langenberg, K. Dickersin Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma a meta-analysis of response, toxicity, and survival Cancer 82 1998 116 126
22. P.A. Kosmidis, M.A. Dimopoulos, C. Syrigos Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group Proc Am Soc Clin Oncol 23 2004 627 (abstr 7058)
23. W.J. Tester, P. Stephenson, C.J. Langer ECOG 1599 Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 627 (abstr 7055)
24. J.F. Sandbach, C. Weissman, R. Brooker A phase II study of weekly docetaxel and carboplatin in stage IIIB (with effusion) or stage IV non-small cell lung cancer patients age < 65 and performance status 2 Proc Am Soc Clin Oncol 23 2004 643 (abstr 7122)
25. M.A. Neubauer, C.H. Reynolds, M. Joppert Preliminary results of a phase II trial utilizing gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2 Proc Am Soc Clin Oncol 23 2004 643 (abstr 7121)
26. H. Spiridonidis, M. Tao, L. Laufman Symptomatic response to non-platinum doublet in performance status 2 (PS2) patients (pts) with non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 688 (abstr 7303)
27. J. Latreille, V. Hirsh, H. Kreisman Sequential therapy with vinorelbine followed by gemcitabine in patients with metastatic non-small cell lung cancer (NSCLC), performance status (PS) 2 or elderly with comorbidities A multicenter phase II trial Proc Am Soc Clin Oncol 23 2004 643 (abstr 7119)
28. V. Alberola, C. Camps, M. Provencio Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer A Spanish Lung Cancer Group phase III randomized trial J Clin Oncol 21 2003 3207 3213
29. E.F. Smit, J.P. van Meerbeeck, P. Lianes (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975 J Clin Oncol 21 2003 3909 3917
30. E. Laack, N. Dickgreber, T. Muller From the German and Swiss Lung Cancer Study Group Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer J Clin Oncol 22 2004 2348 2356
31. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
32. D.G. Pfister, D.H. Johnson, C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline Update 2003 J Clin Oncol 22 2003 330 353
33. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Non-small cell lung cancer, v.1.2004. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed June 24, 2004